EP2158491A4 - Antikörper und verbesserte probenbearbeitungsverfahren zur verwendung in assays für myeloperoxidase - Google Patents

Antikörper und verbesserte probenbearbeitungsverfahren zur verwendung in assays für myeloperoxidase

Info

Publication number
EP2158491A4
EP2158491A4 EP08827464A EP08827464A EP2158491A4 EP 2158491 A4 EP2158491 A4 EP 2158491A4 EP 08827464 A EP08827464 A EP 08827464A EP 08827464 A EP08827464 A EP 08827464A EP 2158491 A4 EP2158491 A4 EP 2158491A4
Authority
EP
European Patent Office
Prior art keywords
myeloperoxidase
assays
antibodies
test sample
sample handling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08827464A
Other languages
English (en)
French (fr)
Other versions
EP2158491A2 (de
Inventor
Saul A Datwyler
David J Hawksworth
Stephen C Hsu
Matthew S Matias
David P Pacenti
Mary S Pinkus
Jessie W Shih
Bryan C Tieman
Joan D Tyner
Robert N Ziemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/750,507 external-priority patent/US20080286818A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP2158491A2 publication Critical patent/EP2158491A2/de
Publication of EP2158491A4 publication Critical patent/EP2158491A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
EP08827464A 2007-05-18 2008-05-16 Antikörper und verbesserte probenbearbeitungsverfahren zur verwendung in assays für myeloperoxidase Withdrawn EP2158491A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/750,507 US20080286818A1 (en) 2007-05-18 2007-05-18 Blood sample handling methods for improved assays for myeloperoxidase
US5006108A 2008-03-17 2008-03-17
PCT/US2008/063930 WO2009023331A2 (en) 2007-05-18 2008-05-16 Antibodies and improved test sample handling methods for use in assays for myeloperoxidase

Publications (2)

Publication Number Publication Date
EP2158491A2 EP2158491A2 (de) 2010-03-03
EP2158491A4 true EP2158491A4 (de) 2011-11-23

Family

ID=40351385

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08827464A Withdrawn EP2158491A4 (de) 2007-05-18 2008-05-16 Antikörper und verbesserte probenbearbeitungsverfahren zur verwendung in assays für myeloperoxidase

Country Status (4)

Country Link
EP (1) EP2158491A4 (de)
JP (1) JP5433570B2 (de)
CA (1) CA2686465A1 (de)
WO (1) WO2009023331A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150198589A1 (en) * 2012-06-15 2015-07-16 Ekrem Erbiz Use of edta tube with gel in elisa method
CN110944689B (zh) 2017-06-07 2022-12-09 施菲姆德控股有限责任公司 血管内流体运动设备、系统和使用方法
WO2019094963A1 (en) 2017-11-13 2019-05-16 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
WO2019152875A1 (en) 2018-02-01 2019-08-08 Shifamed Holdings, Llc Intravascular blood pumps and methods of use and manufacture
US12161857B2 (en) 2018-07-31 2024-12-10 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
WO2020073047A1 (en) 2018-10-05 2020-04-09 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
US11964145B2 (en) 2019-07-12 2024-04-23 Shifamed Holdings, Llc Intravascular blood pumps and methods of manufacture and use
WO2021016372A1 (en) 2019-07-22 2021-01-28 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
EP4010046B1 (de) 2019-08-07 2026-07-15 Supira Medical, Inc. Katheterblutpumpen und zusammenklappbare pumpengehäuse
WO2021062270A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible pump housings
EP4034192B1 (de) 2019-09-25 2025-12-24 Supira Medical, Inc. Intravaskuläre blutpumpensysteme und verfahren zur verwendung und steuerung davon
EP4782050A1 (de) 2019-09-25 2026-07-29 Supira Medical, Inc. Katheterblutpumpen und zusammenklappbare blutleitungen
EP4072650A4 (de) 2019-12-11 2024-01-10 Shifamed Holdings, LLC Absteigende aorten- und hohlvenenblutpumpen
WO2021127503A1 (en) 2019-12-19 2021-06-24 Shifamed Holdings, Llc Intravascular blood pumps, motors, and fluid control
CN111879758A (zh) * 2020-07-28 2020-11-03 江苏扬新生物医药有限公司 一种吖啶酯抗体标记方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117688A2 (en) * 2005-02-11 2006-11-09 University Of Leicester Diagnosis of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724213A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
US5948893A (en) * 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
DK1353666T3 (da) * 2001-01-02 2013-10-14 Cleveland Clinic Foundation Myeloperoxidase, en risikoindikator for cardiovasculær sygdom

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117688A2 (en) * 2005-02-11 2006-11-09 University Of Leicester Diagnosis of heart failure

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
A. NISKANEN ET AL: "Myeloperoxidase (MPO) and hs-CRP as predictive factors for myocardial infarction", CLINICAL LABORATORY INTERNATIONAL, 1 November 2006 (2006-11-01), XP055009479, Retrieved from the Internet <URL:http://www.cli-online.com/uploads/tx_ttproducts/datasheet/myeloperoxidase-%28mpo%29-and-hs-crp-as-predictive-factors-for-myocardial-infarction.pdf> [retrieved on 20111013] *
CAVUSOGLU ET AL: "Usefulness of Baseline Plasma Myeloperoxidase Levels as an Independent Predictor of Myocardial Infarction at Two Years in Patients Presenting With Acute Coronary Syndrome", AMERICAN JOURNAL OF CARDIOLOGY, CAHNERS PUBLISHING CO., NEWTON, MA, US, vol. 99, no. 10, 9 May 2007 (2007-05-09), pages 1364 - 1368, XP022067507, ISSN: 0002-9149, DOI: 10.1016/J.AMJCARD.2006.12.060 *
J. A. VITA: "Serum Myeloperoxidase Levels Independently Predict Endothelial Dysfunction in Humans", CIRCULATION, vol. 110, no. 9, 23 August 2004 (2004-08-23), pages 1134 - 1139, XP055009474, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000140262.20831.8F *
KAMYAR KALANTAR-ZADEH ET AL: "Serum Myeloperoxidase and Mortality in Maintenance Hemodialysis Patients", AMERICAN JOURNAL OF KIDNEY DISEASES, vol. 48, no. 1, 1 July 2006 (2006-07-01), pages 59 - 68, XP055009477, ISSN: 0272-6386, DOI: 10.1053/j.ajkd.2006.03.047 *
MARIE-LUISE BRENNAN ET AL: "Prognostic Value of Myeloperoxidase in Patients with Chest Pain", NEW ENGLAND JOURNAL OF MEDICINE, vol. 349, no. 17, 23 October 2003 (2003-10-23), pages 1595 - 1604, XP055009475, ISSN: 0028-4793, DOI: 10.1056/NEJMoa035003 *
MOCATTA ET AL: "Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial Infarction", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 49, no. 20, 4 May 2007 (2007-05-04), pages 1993 - 2000, XP022079403, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2007.02.040 *
NG ET AL: "Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure", AMERICAN HEART JOURNAL, MOSBY- YEAR BOOK INC, US, vol. 152, no. 1, 1 July 2006 (2006-07-01), pages 94 - 101, XP005686371, ISSN: 0002-8703 *
PINCEMAIL J ET AL: "Fast double antibody radioimmunoassay of human granolocyte myeloperoxidase and its application to plasma", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 137, no. 2, 21 March 1991 (1991-03-21), pages 181 - 191, XP023974059, ISSN: 0022-1759, [retrieved on 19910321], DOI: 10.1016/0022-1759(91)90023-9 *
PUBMEDDEV: "Plasma concentrations of myeloperoxidase p... [J Am Coll Cardiol. 2007] - PubMed - NCBI", 4 May 2007 (2007-05-04), XP055098968, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/17512353> [retrieved on 20140128] *
S. BALDUS: "Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes", CIRCULATION, vol. 108, no. 12, 23 September 2003 (2003-09-23), pages 1440 - 1445, XP055009476, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000090690.67322.51 *
S. J. NICHOLLS: "Myeloperoxidase and Cardiovascular Disease", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 25, no. 6, 1 June 2005 (2005-06-01), pages 1102 - 1111, XP055009482, ISSN: 1079-5642, DOI: 10.1161/01.ATV.0000163262.83456.6d *
T. FRANCK ET AL: "Development of an Enzyme-Linked Immunosorbent Assay for Specific Equine Neutrophil Myeloperoxidase Measurement in Blood", JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION, vol. 17, no. 5, 1 September 2005 (2005-09-01), pages 412 - 419, XP055009472, ISSN: 1040-6387, DOI: 10.1177/104063870501700502 *
TANG W H W ET AL: "Plasma Myeloperoxidase Levels in Patients With Chronic Heart Failure", AMERICAN JOURNAL OF CARDIOLOGY, CAHNERS PUBLISHING CO., NEWTON, MA, US, vol. 98, no. 6, 15 September 2006 (2006-09-15), pages 796 - 799, XP025044842, ISSN: 0002-9149, [retrieved on 20060915], DOI: 10.1016/J.AMJCARD.2006.04.018 *
TSIMIKAS ET AL: "Oxidative Biomarkers in the Diagnosis and Prognosis of Cardiovascular Disease", AMERICAN JOURNAL OF CARDIOLOGY, CAHNERS PUBLISHING CO., NEWTON, MA, US, vol. 98, no. 11, 4 December 2006 (2006-12-04), pages S9 - S17, XP025045056, ISSN: 0002-9149, [retrieved on 20061204], DOI: 10.1016/J.AMJCARD.2006.09.015 *
ZAKI S R ET AL: "Production and characterization of monoclonal antibodies to human myeloperoxidase", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, SAN DIEGO, CA, US, vol. 50, no. 3, 1 March 1989 (1989-03-01), pages 283 - 297, XP022959084, ISSN: 0090-1229, [retrieved on 19890301], DOI: 10.1016/0090-1229(89)90137-2 *
ZHANG RENLIANG ET AL: "ASSOCIATION BETWEEN MYELOPEROXIDASE LEVELS AND RISK OF CORONARY ARTERY DISEASE", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 286, no. 17, 7 November 2001 (2001-11-07), pages 2136 - 2142, XP009084422, ISSN: 0098-7484, DOI: 10.1001/JAMA.286.17.2136 *

Also Published As

Publication number Publication date
WO2009023331A2 (en) 2009-02-19
JP2010527592A (ja) 2010-08-19
EP2158491A2 (de) 2010-03-03
JP5433570B2 (ja) 2014-03-05
WO2009023331A3 (en) 2009-05-28
CA2686465A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
IL216731A0 (en) Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
EP2215460A4 (de) Interne standards und verfahren zur verwendung bei der quantitativen messung von analyten in einer probe
GB2453531B (en) Pre-concentrator and sample interface
IL196458A0 (en) System and method for measuring an analyte in a sample
GB0900421D0 (en) Sample holder for use in biological testing
EP2135048A4 (de) Verfahren und system zur überprüfung hergestellter teile und sortierung der überprüften teile
IL199775A0 (en) Sample handling device
IL206112A0 (en) Methods and apparatus for analyzing samples and collecting sample fractions
GB0812540D0 (en) Laboratory sample archiving apparatus and method
PL2504454T3 (pl) Unikatowe zdarzenie ee-gm3 oraz sposoby i zestawy do identyfikacji takiego zdarzenia w próbkach biologicznych
GB0720264D0 (en) Sample preparation devices and analyzers
PT2367632T (pt) Dispositivo, sistema de análise e método para a condução de ensaios de aglutinação
EP2088441A4 (de) Halteglied zur untersuchung, untersuchungseinrichtung und untersuchungsverfahren
ZA201001253B (en) Reagent kit for sample analysis and sample analysis method
WO2009023331A3 (en) Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
EP2370111A4 (de) Sonde für eine biologische probe und markierungsverfahren und screeningverfahren unter verwendung der sonde
GB0805296D0 (en) Uses of reagents in sample collection and cartridge systems
EP2229028B8 (de) Vorrichtung zur vermessung biologischer proben und system zur vermessung biologischer proben damit
PL2294431T3 (pl) Urządzenie do manipulowania kuwetami i sposób załadunku
EP2274098A4 (de) Multikapillare probenvorbereitungsvorrichtungen und verfahren zur verarbeitung von analyten
EP2278331A4 (de) Leukozyten-analyseverfahren und analysereagens zur verwendung in dem verfahren
IL215322A0 (en) Method for detecting antibody against sith-1 in biological sample
EP2225553A4 (de) Automatisiertes verfahren und vorrichtung zur erkennung von fehlerhafter probenentnahme bei klinischen tests
EP2755029A4 (de) Verfahren zur hemmung der nichtspezifischen bindung in einem schritt zur erkennung einer substanz in einer biologischen probe und mittel zur verwendung in diesem verfahren
EP2133683A4 (de) Vorrichtung zur platzierung histologischer und biologischer proben

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091223

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZIEMANN, ROBERT N.

Inventor name: TYNER, JOAN D.

Inventor name: TIEMAN, BRYAN C.

Inventor name: SHIH, JESSIE W.

Inventor name: PINKUS, MARY S.

Inventor name: PACENTI, DAVID P.

Inventor name: MATIAS, MATTHEW S.

Inventor name: HSU, STEPHEN C.

Inventor name: HAWKSWORTH, DAVID J.

Inventor name: DATWYLER, SAUL A.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZIEMANN, ROBERT N.

Inventor name: TYNER, JOAN D.

Inventor name: TIEMAN, BRYAN C.

Inventor name: SHIH, JESSIE W.

Inventor name: PINKUS, MARY S.

Inventor name: PACENTI, DAVID P.

Inventor name: MATIAS, MATTHEW S.

Inventor name: HSU, STEPHEN C.

Inventor name: HAWKSWORTH, DAVID J.

Inventor name: DATWYLER, SAUL A.

A4 Supplementary search report drawn up and despatched

Effective date: 20111021

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/28 20060101ALI20111017BHEP

Ipc: G01N 33/53 20060101ALI20111017BHEP

Ipc: G01N 33/573 20060101AFI20111017BHEP

17Q First examination report despatched

Effective date: 20121217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140614